TENNOR THERAP-B (06872.HK): Plans H share buyback of up to RMB 50 mln
- The mandate was approved by shareholders at the extraordinary general meeting on 23 October 2026.
- The cap of 5,232,892 H shares equals 10% of the issued H shares, excluding treasury shares, on that date.
- The buyback will be funded by the Company's own resources and capped at RMB 50 million.
NewTimeSpace News: On 26 October 2026, TenNor Therapeutics (Suzhou) Limited (stock code: 06872.HK) said shareholders approved a general mandate to buy back H shares at the extraordinary general meeting on 23 October 2026. The mandate covers up to 5,232,892 H shares, equal to 10% of the total issued H shares (excluding treasury shares) on that date.
The Board said the market price of the H shares does not reflect the Company's intrinsic value and business prospects, and it intends to exercise the mandate on-market from time to time for up to RMB 50 million, funded by its own resources. The Company said the plan will not materially affect its financial position or ordinary business and is in the interests of shareholders. Buybacks will follow its articles of association, the Listing Rules and the Takeovers Code, subject to the general mandate, with no assurance on timing, volume or price.
- HK Recently Listed Stocks Watch | TENNOR THERAP-B (06872.HK): Lock-up on 3.08 Million H Shares Ends Nov 21
- TENNOR THERAP-B (06872.HK): Positive Phase IIa Proof-of-Concept Data for Rifaquizalone (TNP-2092) in Prosthetic Joint Infection; Multicenter Phase IIb Initiated
- TENNOR THERAP (06872.HK): TNP-2092 PJI trial doses first patient
